argenx SE

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
ICLRICON plc -1.30%248.682.8%$140.07m
VRXValeant Pharmaceuticals International, Inc. -5.67%23.6414.1%$139.10m
HZNPHorizon Therapeutics Plc -2.22%84.505.4%$111.32m
CTLTCatalent, Inc. -3.02%99.002.0%$104.46m
BHCBausch Health Cos., Inc. -5.67%23.640.0%$101.75m
JAZZJazz Pharmaceuticals Plc -4.56%130.532.1%$83.60m
SAVACassava Sciences, Inc. -2.67%35.360.0%$83.26m
UTHRUnited Therapeutics Corp. -0.71%198.6513.9%$78.32m
ZGNXZogenix, Inc. -0.14%25.957.5%$77.82m
PRGOPerrigo Co. Plc -3.68%37.416.9%$47.40m
ARGXargenx SE -5.33%264.370.0%$45.84m
PCRXPacira Biosciences, Inc. -3.96%60.929.8%$27.54m
BRBRBellRing Brands, Inc. 4.96%25.630.0%$27.47m
IRWDIronwood Pharmaceuticals, Inc. 0.41%11.049.5%$22.92m
SAGESAGE Therapeutics, Inc. -3.82%36.757.6%$17.22m

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.